Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosis
Reuters2026/08/06 11:07- Roivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a condition with no approved therapies.
- Results will be presented in the future, with BEACON+ topline data expected in 2028.
- The study follows a positive Phase 2 outcome that supported FDA Breakthrough Therapy Designation, positioning brepocitinib as a potential new treatment option.
- Priovant expects a U.S. regulatory decision in dermatomyositis by end-September 2026, supporting a near-term launch path for the drug.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Most Critical Date for the Bullish Cryptocurrency Bill Clarity Act Has Been Set
BPPB posts 1H 2026 net profit of EUR 23.7 million
Valued at 2 trillion! Anthropic may become the largest IPO in history, roadshow starts in October, listing before the midterm elections in November
According to sources familiar with the matter, Anthropic is expected to begin its IPO roadshow as early as mid-October and complete its listing just a few days before the U.S. midterm elections in November.
Top Investor Says XRP Is A Global Agenda. Here’s why
Crypto prices
More
